MBX Biosciences Inc
MBXHealthcare|Biotechnology|USA
$61.05
-4.69 (-7.13%)
Tangible Book
$9.20
Clinical Trials (8)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07699471 A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism | Hypoparathyroidism | P3 | Recruiting | 160 | RCT, Double-blind | Canvuparatide |
| NCT06531941 Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism | Hypoparathyroidism | P2 | Active | 60 | Open-label | 400 µg of MBX 2109 once-weekly by subcutaneous injection, 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection |
| NCT07142707 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity | Obesity | P1 | Recruiting | 124 | RCT, Double-blind | MBX 4291, Placebo |
| NCT07029412 Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI) | Postbariatric Hypoglycemia | P2 | Completed | 20 | Open-label | MBX 1416 (INN imapextide) |
| NCT06465108 Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism | Hypoparathyroidism | P2 | Completed | 64 | RCT, Double-blind | MBX 2109 |
| NCT06036784 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects | Postbariatric Hypoglycemia | P1 | Completed | 69 | RCT, Double-blind | MBX 1416 (Part A), MBX 1416 (Part B), Placebo, MBX 1416 (Part C) |
| NCT06496217 Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function | Renal Impairment | P1 | Completed | 25 | Open-label | MBX 2109, MBX 2109, MBX 2109, MBX 2109 |
| NCT05158335 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects | Healthy | P1 | Completed | 76 | RCT, Double-blind | MBX 2109 (Part A), MBX 2109 (Part B), Placebo |